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AbstrACt
Introduction Delirium is a common complication of 
critical illness, associated with negative patient outcomes. 
Preventive or therapeutic interventions are mostly 
ineffective. Although relaxation-inducing approaches may 
benefit critically ill patients, no well-designed studies 
target delirium prevention as a primary outcome. The 
objective of this study is to assess feasibility and treatment 
effect estimates of a multimodal integrative intervention 
incorporating relaxation, guided imagery and moderate 
pressure touch massage for prevention of critical illness 
delirium and for related outcomes.
Methods and analysis Randomised, controlled, 
single-blinded trial with two parallel groups (1:1 
allocation: intervention and standard care) and stratified 
randomisation (age (18–64 years and ≥65 years) 
and presence of trauma) with blocking, involving 104 
patients with Intensive Care Delirium Screening Checklist 
(ICDSC): 0–3 recruited from two academic intensive 
care units (ICUs). Intervention group participants receive 
the intervention in addition to standard care for up 
to five consecutive days (or until transfer/discharge); 
control group participants receive standard care and a 
sham intervention. We will assess predefined feasibility 
outcomes, that is, recruitment rates and protocol 
adherence. The primary clinical outcome is incidence of 
delirium (ICDSC ≥4). Secondary outcomes include pain 
scores, inflammatory biomarkers, heart rate variability, 
stress and quality of life (6 weeks and 4 months) post-
ICU discharge. Feasibility measures will be analysed 
descriptively, and outcomes will be analysed longitudinally. 
Estimates of effects will be calculated.
Ethics and dissemination The study has received 
approval from the Human Research Ethics Board, 
University of Alberta. Results will inform the design of a 
future multicentre trial.
trial registration number NCT02905812; Pre-results.
IntroduCtIon  
Intensive care unit (ICU) delirium affects 
35%–55% of critically ill patients and is 
independently associated with a 13-fold 
(adjusted OR: 4.88–13.0) increased risk of 
death1 and long-term cognitive impairment.2 
ICU delirium carries important financial 
and societal burdens ((39% higher adjusted 
ICU (95% CI 12% to 72%) and 31% higher 
hospital costs (95% CI 1% to 70%)).3 More-
over, patients identify frightening delirium 
strengths and limitations of this study
 ► We will test feasibility and measures of effect of a 
previously piloted relaxation-inducing intervention 
for the prevention of delirium and improvement of 
related outcomes in critically ill patients.
 ► We will employ an evidence-based, non-pharmaco-
logical multimodal integrative intervention that has 
shown effectiveness for reducing pain and improv-
ing a number of secondary outcomes in a previous 
pilot study.
 ► This pilot aims to assess estimates of effect and fea-
sibility to inform a future trial.
 ► Although clinicians and outcome assessors will be 
blinded, due to the nature of the intervention, partic-
ipants and nurses providing direct care to patients 
cannot be blinded to allocation, although they will be 
blinded to the study hypotheses.
 ► The mechanisms of effects of relaxation-inducing 
interventions in critical illness are not well under-
stood; hence, we aim to explore effects of the inter-
vention on parasympathetic system activation and 
inflammatory markers.
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experiences and pain as the most severe stressors4 5 in crit-
ical care. Pharmacological interventions for the preven-
tion and treatment of delirium have limited benefit 
and are associated with high costs and risks for side 
effects.6 7 Although clinical guidelines recommend the 
development of non-pharmacological interventions to 
prevent delirium,8 effective prevention strategies have yet 
to be established.9 
A prolonged and eventually aberrant stress response 
and depressed parasympathetic (parasympathetic 
nervous system (PNS)) activity have been postulated as 
the pathophysiological basis for the development of both 
ICU delirium and systemic inflammation.10–13 Frightening 
hallucinations and ideations during delirium may further 
exaggerate the stress response and prolong critical illness 
with detrimental consequences. Pain may worsen matters 
by reciprocal incremental feedback on inflammation and 
stress.4 14 Thus, in critical illness, stress, delirium, pain and 
systemic inflammation may comprise a self-perpetuating 
syndrome. Attenuating the cascade of negative health 
impacts from pain and delirium has become a high clin-
ical priority (figure 1).8 Moreover, the growing recogni-
tion that delirium and other critical illness sequelae may 
have long-term consequences in critical illness survivors15 
further highlights the need for prevention strategies.
Evidence-based theoretical work postulates that the 
multitude of psychological stressors in critically ill indi-
viduals may contribute to the development of pathophys-
iological sequelae.10 Moreover, animal models illustrate 
that PNS stimulation and acetylcholine (ACh) release 
suppress inflammation and decrease fatality, via the 
cholinergic anti-inflammatory pathway.16 Devising ways to 
draw on the autonomic nervous systems’ (ANS) inflam-
mation and stress regulatory properties by non-pharma-
cological interventions has, in theory, the potential to 
improve outcomes with low side effect risk. However, stim-
ulation of the PNS in critical care is challenging. Relax-
ation-inducing interventions can induce PNS activity. 
Such approaches have successfully been used in diverse 
patient populations to counter stress but remain under-
tested in critical illness.17 A recent systematic review shows 
favourable effects of relaxation and guided imagery (RGI) 
intervention in reducing pain, anxiety and length of stay 
in critically ill patients,18 whereas the relaxation-inducing 
effects of music in critical care have been well supported 
by evidence.19 In a pilot randomised controlled trial of the 
effects of a similar multimodal intervention on the inci-
dence of pain and on a number of secondary outcomes, 
we observed significant decreases in pain incidence 
(RR=0.56, p=0.003) and severity (p<0.0001), systolic arte-
rial pressure, anxiety, along with improved sleep quality.20
HypotHEsEs
Overall, we hypothesise that a multimodal interven-
tion incorporating RGI and moderate-pressure touch 
massage is feasible within a critical care setting and can 
have an effect on decreasing delirium and in improving 
physiological and psychological outcomes in randomised 
critically patients who will receive standard care and the 
intervention compared with patients receiving standard 
care plus a sham intervention only.
primary hypotheses
We hypothesise that the intervention will be feasible and 
that it will have an effect on decreasing delirium inci-
dence and duration.
Figure 1 Evidence-based framework for the physiological 
mechanism implicated in relaxation-induced effects in critical 
illness. Relaxation acts early at the pathophysiological 
cascade through which an exaggerated stress response 
results in proinflammatory effects, suppressed PNS outflow 
and subsequently in systemic inflammation, multiple 
organ dysfunction and death. The relaxation response 
counterbalances the exaggerated stress response and 
activates PNS and cholinergic anti-inflammatory signalling, 
which downregulates proinflammatory (eg, HMGB-1) 
and upregulates anti-inflammatory cytokines, therefore 
attenuating systemic inflammation and its detrimental organ 
effects. α7-nAChR, alpha7-nicotinic acetylcholine receptor; 
HMGB-1, high mobility group box 1; ICU, intensive care unit; 
PNS, parasympathetic nervous system.
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secondary hypotheses
We hypothesise that the intervention will have an effect 
on: (A) incidence rate of subsyndromal delirium, time to 
delirium occurrence and proportion of delirium-free time 
during up to 8 days of ICU stay; (B) sedation levels and 
daily sedative, analgesic and antipsychotic agent dose; (C) 
pain occurrence and intensity; (D) perceived stress level; 
(E) sleep duration and quality; (F) anxiety; (G) length of 
ICU stay and duration of mechanical ventilation/propor-
tion of mechanical ventilation-free days; (H) hospital 
length of stay (LOS), (I) physiological biomarkers; and 
(K) quality of life after ICU discharge.
dEsIgn And MEtHods
study design
Relaxation for Critically ill Patient Outcomes and Stress-
coping Enhancement is a pilot feasibility, randomised, 
controlled, single-blinded trial with two parallel groups 
(intervention and standard care). Accounting for major 
risk factors of delirium,15 stratified randomisation 
according to age (18–64 years and ≥65 years) and pres-
ence of either surgical or trauma injury with blocking and 
1:1 allocation to assure balance in numbers per group will 
be employed.
research objectives
Research objectives include to:
a. Assess clinical trial feasibility with predefined goals 
(enrolment, randomisation, adherence, timing of in-
tervention and workload).
b. Calculate estimates and variance of treatment effect 
across outcome measures.
c. Calculate CI of incidence proportions, means and SD 
of outcome measures in study groups.
d. Explore the feasibility of identifying underlying physi-
ological mechanisms.
setting, recruitment and sample size
Consecutive patients admitted to two academic ICUs, 
in Edmonton, Alberta, Canada, with an Intensive Care 
Delirium Screening Checklist (ICDSC) score of 0–3 will 
be screened for study eligibility and will be recruited by 
research staff at each site. In cases where an ICDSC score 
cannot be obtained on admission, we will screen patients 
for up to 4 days after admission. Since delirium occurs 
most often within the first 5 days of admission, screening 
and enrolment will take place as soon as possible and 
within 96 hours after ICU admission. This pilot is not 
powered to determine a difference in a primary outcome, 
since we aim to assess estimates of effect. For a defini-
tive trial, we would require 290 (145/arm) patients to 
detect a 10% difference in incidence proportion between 
intervention (20%) and control (30%) arm (two-sided 
alpha=0.05, power=80%, dropout rate=10%). The Pan 
method,21 which is based on generalised estimating equa-
tions, was used to perform the sample size calculation 
under the assumption of AR1 correlation structure among 
5 days repeated measurements with correlation between 
any two adjacent observations from the same subject of 
0.5. Since this is a pilot, aiming to explore feasibility and 
estimates of effects, and the incidence rates used for the 
calculation might not be appropriate, we used 36% of the 
sample size of the full study to estimate the parameters 
accurately and get an experience for a full trial.22
Eligibility
Inclusion criteria: (A) age over 18 years, (B) ICDSC: 0–3 
and (C) written informed consent by participant or by family 
member/surrogate in case participant not capable.
Exclusion criteria: patients: (A) already in the ICU for 
more than 96 hours, (B) with ICDSC >3 within 72 hours 
of screening in case intervention has not been initiated, 
(C) on special contact precautions (ie, Methicillin-re-
sistant Staphylococcus aureus (MRSA), Vancomycin-re-
sistant enterococci (VRE) and HIV), (D) with expected 
ICU LOS <72 hours, (E) with acute neurological illness/
neurological trauma, persistent deep sedation or coma 
(Richmond Agitation Sedation Scale (RASS=−4 and –5)), 
(F) with current history of severe mental health problems 
and dementia, as per history, (G) with hearing impair-
ment or conditions not permitting use of headphones, 
(H) on neuromuscular blockers, (I) with known or 
suspected substance/alcohol withdrawal and (J) enrolled 
in trials of sedatives and antipsychotics.
patient and public involvement
The protocol is based on a pilot study with 60 randomised 
patients,20 12 of which provided feedback regarding 
the desirability, burden and specific components of the 
intervention, study procedures and preferred outcomes. 
Participants’ feedback informed the design of the 
study, resulting in many significant changes. Preferred 
post-ICU follow-up times were informed by an informal 
advisory group through the Alberta Innovates’ Strategy 
for Patient Oriented Research network of patient repre-
sentatives. Moreover, as a patient and clinician engage-
ment strategy, an advisory group with representatives of 
patients, families and clinicians will act as a consultation 
group for the research team. Acceptance and desirability 
of the protocol by clinicians and patients/families will be 
assessed further by focus group discussions. Recommen-
dations will inform future development of the interven-
tion and research design. Canadian Institutes of Health 
Research guidelines for patient engagement will be used 
to establish and facilitate the advisory group. Feedback 
on: (A) concerns on the intervention, study processes 
and contamination of the control group by implemen-
tation of aspects of the intervention, (B) desirability of 
intervention (massage, music choices, complexity, voice 
of recording and pace), (C) timing within the day, (D) 
duration/feasibility of the intervention, (E) burden of 
study processes, (F) outcomes to be addressed in the 
future trial, (G) interpretation of results and (H) strate-
gies for dissemination of findings will be collected.
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IntErvEntIon
The choice of a multimodal intervention (duration: 
55 min) was based on an evidence-based literature review, 
its superiority to unidimensional approaches,23 the recom-
mendations of the American Holistic Nurses Association24 
and a successful pilot.20 According to the UK Medical 
Research Council guidance for complex intervention 
trials,25 development of the protocol included extensive 
theoretical work,10 two systematic reviews,18 26 model-
ling of outcomes, extensive consultations with groups 
of experts, one small feasibility and acceptability pilot 
(n=10 participants) and one larger pilot (n=60)20 and 
consultation with pilot participants and patients’ repre-
sentatives. The intervention has been developed by the 
research team and a group of experts based at the Univer-
sity of Alberta and Cyprus University of Technology. It 
includes: (A) a brief moderate-pressure massage session 
(massage: 15 min) and (b) RGI (30 min, through head-
phones). The 30 min recorded RGI intervention involves: 
(A) guided relaxation, (B) a structured guided imagery 
script supported by instrumental music and (C) recorded 
instrumental music for 15 min (Haydn concerto no 1 in C 
major and Bach violin concerto in D minor, 60 beats per 
min approximately). The same recorded RGI script will 
be used at all sessions. It includes positive suggestions and 
instructions for gradual relaxation, followed by guidance 
to visualise one’s body being healed. Moderate-pressure 
(4 N, approximately or patient pressure rating 3/10) low 
velocity (1–5 cm/s) massage consists of broad and repeti-
tive circular movements with wide area of contact, applied 
sequentially for 2–3 min at each site: hands, forearms, 
lateral arms and then over trapezius muscles, the temple, 
scalp, face and forehead area. Areas are to be contacted 
as appropriate to each participant, and the protocol may 
be adapted taking into account safety issues (ie, to avoid 
area around intravascular catheter or injury). Moderate 
pressure massage is involved in PNS activation, in contrast 
to light pressure.27 The intervention will be administered 
once daily (09:00–15:00) for up to five consecutive days 
by trained research staff not involved in patient care, who 
will be randomly audited by the Trial Steering Committee 
(TSC) to ensure protocol adherence. The decision to 
deliver the intervention for the first 5 days after enrol-
ment only was based on epidemiological data regarding 
the onset of delirium,9 data on median length of stay of 
the target populations in the study institutions and cost 
considerations. However, it will be important to study the 
effect of the intervention on longer stay patients in future 
trials. The decision to deliver only one intervention daily 
was based on a small acceptability/feasibility pilot and 
pragmatic considerations for knowledge translation and 
future implementation of this approach, as well as cost 
considerations and burden to participants and units. The 
durations of guided imagery, music listening and touch 
intervention were based on the acceptability pilot, expert 
opinions on the minimum duration to achieve a relaxation 
effect and on published evidence.18 Despite evidence on 
the importance of providing choice to patients regarding 
music listening,19 we will use standardised music for inter-
vention stability purposes. It will be important to look at 
the effect of patient-directed music in future trials of this 
intervention.
Interruptions and deviations from the intervention 
protocol will be recorded in detail. The intervention will 
be terminated on a patient’s transfer or discharge from 
the ICU. The intervention may be discontinued in case of 
adverse events related to the intervention or withdrawal 
of consent. If we observe ICDSC scores above 3 once the 
intervention has been commenced, the intervention will 
be continued, unless otherwise indicated by a participant’s 
condition. Although contamination of the control group 
by spontaneously mimicking aspects of the intervention 
by healthcare personnel cannot be excluded, health-
care providers in the units are very familiar with clinical 
trials and have been instructed on the need to abstain 
from mimicking the intervention. Additionally, the touch 
component of the intervention requires specific training 
and it is unlikely to be successfully replicated.
randomisation and allocation concealment
Participants will be randomly assigned to either control 
or intervention group (1:1 allocation) as per a comput-
er-generated randomisation schedule, generated by the 
EPICORE, University of Alberta, stratified by site, age 
(18–64 years and ≥65 years) and presence of surgery 
or trauma using permuted blocks of random sizes. The 
block size will not be disclosed to ensure concealment. 
After baseline measurements, allocation will be disclosed 
only to the intervention staff. Codes will be generated 
prior to the beginning of the study by EPICORE.
blinding
Investigators, physicians and nurses (when possible), data 
collectors, research assistants and laboratory technicians 
will be blinded to group allocation during the trial and 
analysis. Due to the nature of the intervention, partici-
pants cannot be blinded to allocation. Also, participants’ 
primary nurses cannot be blinded to study procedures (ie, 
delivery of massage); however, they will remain blinded to 
study hypotheses and study design (ie, study outcomes and 
numbers and types of participants’ groups), to minimise 
performance bias. We believe that these procedures along 
with the sham intervention will maintain an adequate level 
of concealment even among participants’ primary nurses 
to minimise bias. The same intervention personnel will be 
involved in the delivery of the intervention and sham inter-
vention. Intervention personnel are not involved in assess-
ment of patient outcomes and have been trained on the 
importance of preserving blinding, therefore minimising 
the risk for potential bias.
treatment arms
Patients randomly allocated to the intervention group 
will receive the intervention in addition to standard care 
(standard care+multimodal intervention group). Patients 
allocated to the control group will receive standard 
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care and a sham intervention consisting of presence of 
a research staff at the bedside with drawn curtains and 
silent headphones (standard care+sham intervention 
group; schematic of study design in figure 2).
Concomitant care
Standard care will be continued for all participants. Type 
and dose of all administered sedative, psychoactive and 
analgesic medication will be recorded.
duration of participation
The total duration may vary according to ICU length of 
stay and will be 17 weeks approximately, from enrolment 
until the last follow-up at 4 months post-ICU discharge.
dAtA CollECtIon And InstruMEnts
Data will be collected for each participant by blinded data 
collectors and captured in a Research Electronic Data 
Capture (RedCap) database developed and monitored by 
EPICORE. Time points include: baseline measurements, 
follow-up while in the ICU for up to 5 days, follow-up 
48–96 hours after ICU discharge, follow-up 6 weeks and 4 
months after ICU discharge. In case of participants who 
discontinue participation, data already collected will be 
retained.
All study scales are routinely used in clinical prac-
tice and have established psychometric properties. 
The ICDSC is one of the most reliable tools for assess-
ment of ICU delirium advocated by recent guide-
lines.4 28 Interobserver reliability of and sensitivity 
(80.1, 95% CI 73.3 to 85.8) of ICDSC have been estab-
lished and will be further assessed in this study.28 For 
comatose, deeply sedated patients (RASS=−4 and –5) 
delirium cannot be assessed. Data captured on case 
reports forms are included in figure 2. Baseline data 
captured at enrolment will include: sociodemographic 
Figure 2 Schematic of study design. Ach, acetylcholine; APACHE, Acute Physiology & Chronic Health Evaluation; C-POT, 
Critical Care Pain Observation Tool; CRP, C reactive protein; EQ-5D, EuroQol Five Dimensions Questionnaire; HADS, Hospital 
Anxiety and Depression Scale; HF, high frequency; HMGB, high mobility group box; HRV, heart rate variability; ICDSC, Intensive 
Care Delirium Screening Checklist; ICU, intensive care unit; IQCODE, Informant Questionnaire on Cognitive Decline in the 
Elderly; IV, intravenous; LF, low frequency; LOS, length of stay; NRS, numeric rating scale; RASS, Richmond Agitation Sedation 
Scale; SOFA, sequential organ failure; STAI, State Trait Anxiety Inventory.
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data, admission diagnosis, history of alcohol use, medi-
cations prior to admission, metabolic acidosis, ICDSC, 
RASS, Short Form Informant Questionnaire on 
Cognitive Decline in the Elderly, Pre-Deliric Delirium 
Risk Score, baseline intravenous sedation, analgesia 
and antipsychotic dose, disease severity at admission 
(Acute Physiology & Chronic Health Evaluation II 
(APACHE II), Sequential Organ Failure Assessment 
(SOFA)), number of days in hospital and ICU prior to 
protocol enrolment. For pain, scores obtained at the 
first preintervention measurement will be considered 
as baseline.
outCoME MEAsurEs
Primary and secondary outcome, as well as feasibility, 
measures include (online supplementary appendix 1):
primary clinical outcome
Incidence rate of delirium (ICDSC ≥4), during 5 days 
of intervention (first 5 days of enrolment). Presence of 
delirium will be assessed by blinded trained nurse asses-
sors two times daily (08:00 and 20:00).
secondary outcomes (estimates, variance of effects, 
proportions and means, and sd (where applicable) per group)
1. Delirium-related secondary outcomes: (A) incidence 
rate of delirium (ICDSC ≥4) during ICU stay and 
postintervention, (B) incidence rate of subsyndromal 
delirium (ICDSC: 1–3) during the intervention period 
and subsequent ICU stay, (C) time to delirium occur-
rence, (D) proportion of delirium-free time during up 
to 8 days of ICU stay (excluding periods with deep se-
dation and coma), (E) sedation levels (RASS score and 
(F) daily sedative (benzo-equivalents and propofol), 
analgesic (morphine equivalents) and antipsychotic 
agent (type, mg/24 hours) dose.
2. Pain-related outcomes (preintervention and postin-
tervention): (A) pain intensity (self-reported (S-R) nu-
meric rating scale (NRS) for patients able to self-report, 
pain indicators (Critical Care Pain Observation Tool in 
patients unable to self-report and (B) perceived stress 
level (S-R NRS).
3. Sleep (daily): (A) sleep quality (S-R NRS) and (B) 
sleep duration (in min) ((sleep monitors (Fitbit Alta 
HR: daily sleep cycle) and nurses’ log (duration of 
sleep between 19:00–07:00)). Although more reliable, 
due to considerations around burden to the unit and 
cost, we do not use polysomnography in this pilot.
4. Disease severity (daily): SOFA score.
5. Physiological biomarkers (preintervention and postin-
tervention): (A) serum inflammation biomarkers 
(high mobility group box 1 (HMGB-1) and C reactive 
protein (CRP) levels), (B) high frequency (HF) and 
low frequency (LF) components of heart rate variabil-
ity (HRV) as measures of PNS status and (C) serum 
ACh levels, as a measure of PNS activation. The choice 
of biomarkers was based on the theoretical framework 
guiding this work (triggering of a relaxation parasym-
pathetic response and attenuation of the inflammatory 
response; figure 1) and results of the pilot study,20 29 
which showed alterations in biomarkers immediately 
postintervention and overtime, despite great variability 
in biomarker levels. The results will help us generate 
more informed hypotheses for a subsequent trial.
6. Psychological outcomes (2–7 days after ICU discharge): 
anxiety (Hospital Anxiety and Depression Scale and 
State Trait Anxiety Inventory-6):
1. Clinical outcomes (at discharge): (A) length of 
ICU stay (ICU LOS) (or ward-ready), (B) duration 
of mechanical ventilation/proportion of mechani-
cal ventilation-free days, (C) survival, (D) hospital 
LOS and (E) (3 months post-ICU discharge): 90-day 
survival.
2. Quality of life outcomes (6 weeks and 4 months 
post-ICU discharge): EuroQol Five Dimensions 
Questionnaire and Short-Form 36 Health Survey.
3. Recollection and perception of the intervention 
(2–7 days after ICU discharge and 6 weeks post-
ICU discharge): qualitative open-ended questions 
to explore recollection of intervention, views on in-
tervention and acceptability (online supplementary 
appendix 2).
Feasibility
1. Acceptability: number of patients refusing or wish-
ing to discontinue a session. Acceptability will be fur-
ther assessed with the patients and clinicians advisory 
group.
2. Enrolment and consent: (A) percentage (%) of eligi-
ble patients and reasons for non-eligibility, (B) time 
from admission to enrolment, (C) recruitment rates 
and (D) percentage of patients declining consent.
3. Randomisation and concealment: (A) time from en-
rolment to randomisation, (B) percentage of of cases 
at which allocation was inappropriately revealed and 
description of incident.
4. Protocol adherence and intervention fidelity: percent-
age of: (a) participants completing the entire study 
protocol, (B) sessions missed, interrupted and delayed, 
and reasons. Adherence to intervention protocol as-
sessed by random observation audits and by interven-
er’s detailed reports of any deviations from protocol 
and related reasons.
5. Data collection and management: (A) timeliness, accu-
racy of data collection and reliability, (B) testing of tri-
al database, (C) type and percentage of missing values, 
(D) qualitative data on participants’ perceptions of the 
study and (E) time required for all study procedures 
and intervention (to be used in future economic as-
sessment and assessment of burden of the trial).
primary feasibility criteria
The study will be considered feasible for the specific 
population and ICU context if the following five criteria 
are met:
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a. Eligible patients declining consent <60%.
b. Cases at which allocation was inappropriately revealed 
<3%. 
c. Participants withdrawing from study protocol while 
still in the ICU <10%. 
d. Average sessions missed per patient <40%. 
e. Average sessions interrupted per patient <50%.
bIoMArkEr quAntIFICAtIons
blood sampling
One 5 mL blood sample will be collected in precoded 
general anticoagulated phials, through an intravascular 
catheter already in place, within 10 min before and 10 min 
after the intervention.
biomarker analyses
Serum levels of HMGB-1, ACh and CRP
These will be quantified by commercially available sand-
wich ELISA kits (LifeSpan Biosciences, Seattle, Wash-
ington, USA; Biosource, S. Diego, California, USA; R & 
D Systems, Minneapolis, Minnesota, USA< respectively). 
Intra-assay and interassay coefficients of variation are 
expected to be less than 10%. All samples will be tested 
within the same assay run in duplicate by a specialised 
laboratory technician. Measurements will be carried out 
at the Women’s Health Research Laboratory, Faculty of 
Nursing, University of Alberta.
ANS activity: HF, LF AND LF/HF ratio
ANS activity will be assessed through frequency domain 
analysis of ECG recordings. ECG recordings will be logged 
using the Zephyr BioModule, and data will be imported 
into the OmniSense software. Data from OmniSense 
will then be uploaded to Kubios HRV software (Kubios 
HRV – Hear Rate Variability Analysis Software), and HF, 
LF and LF/HF ratios will be computed. HRV data will be 
recorded continuously starting from 5 min before, during 
and 5 min after the intervention. For ease of incorporation 
into statistical models, HRV components will be analysed 
at 5 min before the intervention, 5 min after the interven-
tion and several times during the intervention based on 
the timing of its various components. Specifically, HRV 
components will be will be analysed on the 8th and 15th 
min of massage (half-way and conclusion of massage), 3rd 
and 15th min of RGI (induction and conclusion of RGI) 
and end of music therapy.
dAtA AnAlysIs
statistical methods
Demographic/clinical characteristics of patients and all 
outcomes will be presented by treatment group using 
descriptive statistics: mean (SD), median (IQR) or propor-
tion. Outcomes will be analysed longitudinally over 5 days 
by logistic regression model based on generalised estimating 
equations (GEE) with first-order autoregressive correlation 
structure (AR1) correlation structure. Analysis of covari-
ance, t-test or Mann-Whitney U test, as appropriate, will be 
conducted for the continuous outcomes that are not longi-
tudinal. Models will be adjusted for covariates including 
predeliric score, administration of medication (sedatives, 
analgesics, vasoactives and antipsychotics) and severity score 
(SOFA and APACHE). χ2 or exact test, as appropriate, will be 
used for categorical outcomes. We will treat pain outcomes as 
both categorical (presence or absence of pain) and contin-
uous variables (pain score). CIs will be presented with esti-
mated effects. Primary analysis will be based on all available 
data using data from all assessments. Since GEE assumes 
missing completely at random (MCAR) mechanism, we plan 
to conduct a sensitivity analysis based on inverse probabili-
ty-weighted GEE,30 which employs a less restrictive missing 
at random (MAR) mechanism. A ‘last observation carried 
forward’ (LOCF) approach was not considered because 
analysing all available data performs better than LOCF 
in GEE setting with respect to bias, type I error rate and 
coverage probability under both MCAR and MAR mecha-
nisms. Although we are not able to formally assess potential 
effects of the sham intervention with the current two-group 
design, GEE models will provide indications of such poten-
tial effects that will be taken into account at a future trial. 
Analysis will be conducted by EPICORE.
To account for non-compliance, protocol deviations and 
missing outcomes, intention-to-treat (ITT) analysis will be 
employed. ITT analysis includes every randomised subject 
according to treatment assignment. Additionally, per-pro-
tocol (PP) analysis will also be employed. PP population is 
defined as a subset of the ITT population who completed 
the study without any major protocol violations. If ITT and 
PP analyses lead to similar conclusions, the reliability of 
results will be supported. Although this is a pilot trial, ITT 
will help reduce potential effects of selection bias. PP analysis 
will assess whether the ITT result is too conservative. This 
will provide important data regarding the effect size for the 
subsequent trial. Both analyses will assist us in revising the 
protocol for the larger trial.
qualitative analyses
Interview transcriptions will be thematically analysed 
by an inductive content analysis approach.31 A coding 
scheme will be developed based on recurrent themes of 
the first five interviews. Subsequently, two researchers 
(EDEP and TP) will code independently, using axial and 
inductive coding to formulate a final coding template by 
consensus. The final coding scheme will then be used to 
code, compare and interpret all transcripts. Individual 
analyses of the team members will be discussed to achieve 
shared understanding and to increase reliability. The data 
will be analysed via NVivo software (QSR International 
Doncaster, Victoria, Australia).
quAlIty Control And quAlIty AssurAnCE
This pilot will be supervised by an independent TSC, 
consisting of three clinical trial experts independent 
of the research team. Periodical audits of the inter-
vention and trial processes at both sites by personnel 
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independent from investigators will be initiated by the 
TSC. Randomisation, recruitment, intervention adher-
ence, blinding, stability and data collection processes 
will be monitored. Trial Monitoring Committee will also 
review relevant information from similar studies and 
will consider the recommendations of the Data Moni-
toring and Ethics Committee. Study personnel have been 
trained to standardise processes. We have developed two 
training videos including detailed demonstration of the 
intervention. Moreover, research personnel involved with 
the intervention has received 18–21 hours of hands-on 
training, including detailed auditing, and several hours 
of self-paced training to standardise the process, commu-
nication and timing of intervention. Study personnel will 
meticulously record any deviations from the interven-
tion protocol to assess feasibility and effect on outcomes. 
Clinical data will be retrieved from the quality-controlled 
clinical information system of the units. Detailed elec-
tronic data collection forms with embedded quality 
controls will be used and reviewed in detail. Data quality 
will be monitored through EPICORE before, during and 
after entry. All data will be entered electronically using 
study forms generated through RedCap with embedded 
quality control processes. Study data will be collected and 
managed using REDCap electronic data capture tools 
hosted at the University of Alberta.32 A quality control 
system will be applied for biological measurements 
as per lab protocol. Day-to-day operations of the trial 
will be overseen by a Trial Management Group (TMG) 
comprising, as a minimum, the principal investigator, 
senior trial manager, trial manager, trial statistician and 
data manager. TMG meetings will take place on a regular 
basis throughout the duration of the study. The TMG will 
have responsibility for ensuring the adherence and prog-
ress of the study in relation to all regulatory, administra-
tive academic and any clinical or safety issues.
EtHICs
This study will be conducted in compliance with Cana-
dian and International Good Clinical Practice standards. 
No deviation from the protocol will be implemented 
without the prior review and approval of the Human 
Research Ethics Board (HREB) except where it may be 
necessary to eliminate an immediate hazard to a research 
participant. In such case, the deviation will be reported 
to the HREB.
Experienced research personnel not involved with 
the delivery of the intervention and in patient care will 
acquire informed consent from legal surrogates or partic-
ipants if competent to consent. Participant assent will be 
acquired when participants regain capacity. Confidenti-
ality, anonymity and right to withdraw at any point with 
no questions asked and no effect on the quality of care 
received will be assured. After completion of the study, 
the data and samples will remain stored at the academic 
institution for 5 years.
Confidentiality
Code-identified encrypted study data will be stored sepa-
rately from participant information at an EPICORE data-
base permitting code-access only. All study forms, lab 
specimens and data will be identified by an alphanumeric 
code to maintain confidentiality. Records that contain 
names and identifiers will be stored separately from study 
data identified by code. Participants’ information will not 
be released outside the study. Participant information will 
be stored at an encrypted limited code-initiated access 
electronic file. Consent forms will be kept in a locked 
file cabinet at a prespecified limited-access room at the 
University of Alberta.
sAFEty
Although prior pilot data did not provide evidence of 
adverse effects or increased rate of complications, any 
physiological/behavioural alteration during interven-
tions will be recorded and analysed. Adverse events, 
irrespective of causal relationship, will be collected for 
all participants during and up to half an hour after the 
intervention.
dAtA dIssEMInAtIon
Results will be disseminated to participants, healthcare 
professionals, health services authorities and the public 
via conference presentations and publications. Results of 
this study will be used to inform the design and conduct 
of a future multicentre trial. The results of the trial will 
be presented at national and international meetings and 
published in peer-reviewed journals. A lay summary of the 
results will be available to trial participants on request. 
An online summary of the findings will also be made 
available.
ConClusIons
This pilot clinical trial integrates a low-risk, patient-cen-
tred strategy, translational research and psychological 
outcomes to allow an evaluation of non-pharmacological 
delirium management with mechanistic insights. Implica-
tions of the definitive trial include the potential to reassure 
patients, decrease the incidence of frightening delirium 
experiences and improve longitudinal outcomes.
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